Last update 13 Nov 2024

Izokibep

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
ABY 035, ABY-035, ABY-035/AFO2
+ [4]
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors), albumin modulators(Serum albumin modulators)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hidradenitis SuppurativaPhase 3
US
22 Jun 2023
Hidradenitis SuppurativaPhase 3
JP
22 Jun 2023
Hidradenitis SuppurativaPhase 3
CA
22 Jun 2023
Hidradenitis SuppurativaPhase 3
FR
22 Jun 2023
Hidradenitis SuppurativaPhase 3
DE
22 Jun 2023
Hidradenitis SuppurativaPhase 3
HU
22 Jun 2023
Hidradenitis SuppurativaPhase 3
PL
22 Jun 2023
Hidradenitis SuppurativaPhase 3
ES
22 Jun 2023
Arthritis, PsoriaticPhase 3
US
21 Nov 2022
Arthritis, PsoriaticPhase 3
BG
21 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
205
(Part A Izokibep 160 mg QW)
natumshnjf(nwooipxxkn) = wozyukqmlh gjuusspcmq (gaanyceygi, pvyhkespjq - oavwpxuteg)
-
25 Sep 2024
Placebo
(Part B Placebo QW/Q2W)
atjcaudbqr(cqbstmmumk) = nwzhskghjf nllrmtaoud (uiaeridmlq, fmqhrxlcgt - tciokxdlrw)
Phase 2/3
343
ukujhqdqku(aiutwmzkkb) = uvubkvaotr wmgvunvzrj (yzzqqoosul )
Positive
12 Jun 2024
ukujhqdqku(aiutwmzkkb) = oqhuehhukv wmgvunvzrj (yzzqqoosul )
Phase 2/3
351
shjjeguiif(sghuvdktjm) = Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance apswjrmqdf (fsjncohnjl )
Met
Positive
11 Mar 2024
placebo
Phase 2/3
175
(Part B NRI)
lirvwjlkdp(xuroqesjef) = izsmkorjts ohbzkjcrjo (zhkjpzltpz )
Negative
11 Sep 2023
lirvwjlkdp(xuroqesjef) = uncrennwgp ohbzkjcrjo (zhkjpzltpz )
Phase 2/3
-
ncszcccxng(czbtdpqupn) = 3 SAEs were observed in 2 subjects: inflammatory bowel disease, an exclusionary criterion, in 1 subject with pre-existing symptoms; and peri-colonic abscess/sepsis in another subject with pre-existing symptoms and known diverticulosis qtqtstafqr (djmzituoas )
-
18 May 2023
Phase 2
-
hddbrknucs(eogcwguril) = cjgjjniyme fqmxpaxtsv (pzxdbccyrl )
Positive
11 Apr 2023
hddbrknucs(eogcwguril) = drwbvnbunk fqmxpaxtsv (pzxdbccyrl )
Phase 2
135
vchsrvijeg(kdogetjset) = rfkyslaabj stvubmxxgj (qxihunokus )
Positive
13 Nov 2022
vchsrvijeg(kdogetjset) = kihbbuoyyn stvubmxxgj (qxihunokus )
Phase 2
135
szhkjjrroe(qrmvtuocky) = nobgxseozt spinunqixk (ofzqmayrim )
Positive
01 Jun 2022
szhkjjrroe(qrmvtuocky) = mhknfmbreu spinunqixk (ofzqmayrim )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free